Following unconfirmed reports that Abbott (ABT) is nearing a potential acquisition of Exact Sciences (EXAS), BofA moves to No Rating, citing the belief that the stock is no longer trading on fundamentals.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Buy Rating Maintained Amid Speculation of Abbott’s Strategic Acquisition of Exact Sciences
- Buy Rating for Exact Sciences Amid Potential Abbott Labs Acquisition and Growth Prospects
- Strategic Acquisition Potential: Abbott’s Interest in Exact Sciences Enhances Investment Appeal
- William Blair says Exact Sciences takeout price likely needs to be over $100
- Abbott weighs takeover of cancer test maker Exact Sciences, Bloomberg says